Cephalon Inc. has hit Apotex Corp. with a lawsuit that accuses the rival drug manufacturer of infringing a pair of patents for Nuvigil®, in an attempt to block a generic version of the stimulant from entering the market. Apotex infringed the two patents by submitting an abbreviated new drug application (ANDA) to make and sell the Nuvigil® generic armodafinil to the U.S. Food and Drug Administration, according to a complaint filed Thursday in the U.S. District Court for the Southern District of Florida. The patents-in-suit involve methods for producing drugs used to treat daytime sleepiness associated with sleep apnea, narcolepsy, and work shift sleep disorder. Cephalon is represented by Finnegan.
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Press Release
District Court Rules in Favor of Finnegan Client Cephalon to Uphold Patent for Nuvigil®
March 30, 2013
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.